James Brumley

James Brumley

InvestorPlace Feature Writer

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Secondary Offerings: Friend or Foe?

By James Brumley, InvestorPlace Feature Writer

There are reasons to like (and dislike) a secondary offering ... but they usually have little to do with the offering itself.

The Market Says Obamacare Is Here to Stay

By James Brumley, InvestorPlace Feature Writer

The relative performance of the healthcare sector's industries says investors expect Obamacare to survive the debt-ceiling battle.

3 Warnings Before You Play With Inverse ETFs Like DUST

By James Brumley, InvestorPlace Feature Writer

What's the best way to use, or best reason to avoid, a bearish leveraged gold fund like the Direxion Daily Gold Miners Bear 3X Shares (DUST)? That depends.

Roche’s Breast Cancer Drug Approval Is Just the Beginning

By James Brumley, InvestorPlace Feature Writer

It might have been dismissed as irrelevant by most investors, but Roche and its Perjeta could reshape the breast cancer drug landscape.

3 Stocks That Don’t Care About a Government Shutdown

By James Brumley, InvestorPlace Feature Writer

In the unlikely event a government shutdown is allowed to materialize for any length of time, these three investment types should hold up despite the freeze.

Gold & Silver’s Weak Q3 Should Improve in Q4

By James Brumley, InvestorPlace Feature Writer

What will happen to gold and silver in the fourth quarter of 2013? The way things took shape in the third quarter has a lot to do with it.

5 Stocks Leading the Generic Drug Charge

By James Brumley, InvestorPlace Feature Writer

As pervasive as generic drug usage has already become, experts say there's still lots of room to grow. These companies are leading that charge.

Meet the New ‘Gold Standard’ for Flu Vaccines

By James Brumley, InvestorPlace Feature Writer

This seemingly minor upgrade to 2013's key flu vaccines is not only a bigger deal than most presume, but what's in the works could be even bigger.

Shoot for the Moon With This Rocket Stock

By James Brumley, InvestorPlace Feature Writer

It's long overdue, but the era of the federal government outsourcing key tasks to those better suited is finally here, and Orbital Sciences is out in front.

Do We Really Care About a Keurig Store?

By James Brumley, InvestorPlace Feature Writer

Green Mountain joins the likes of Apple, Tesla and Microsoft by establishing a retail store, but how big of a deal are Keurig stores for shareholders?

Load More